Giuseppe Alberto Palumbo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8071512/publications.pdf

Version: 2024-02-01

210 papers	5,207 citations	94269 37 h-index	114278 63 g-index
216 all docs	216 docs citations	216 times ranked	6922 citing authors

#	Article	IF	Citations
1	Mutation and Haplotype Studies of Familial Mediterranean Fever Reveal New Ancestral Relationships and Evidence for a High Carrier Frequency with Reduced Penetrance in the Ashkenazi Jewish Population. American Journal of Human Genetics, 1999, 64, 949-962.	2.6	280
2	Autologous haematopoietic stem-cell transplantation versus bortezomibâ€“melphalanâ€“prednisone, with or without bortezomibâ€“lenalidomideâ€“dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematology,the, 2020, 7, e456-e468.	2.2	244
3	M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro. Journal of Immunology, 2009, 182, 4415-4422.	0.4	227
4	Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib. Frontiers in Oncology, 2019, 9, 1186.	1.3	142
5	Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Restoration of Age-Associated Decline of Thymus Weight, Thymic LHRH Receptors, and Thymocyte Proliferative Capacity. Endocrinology, 1989, 125, 1037-1045.	1.4	133
6	Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematology,the, 2017, 4, e127-e136.	2.2	132
7	CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leukemia Research, 2009, 33, 1212-1216.	0.4	124
8	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer, 2020, 126, 1243-1252.	2.0	106
9	Azacitidine for the treatment of lower risk myelodysplastic syndromes. Cancer, 2010, 116, 1485-1494.	2.0	98
10	Risk factors for genital prolapse in non-hysterectomized women around menopause. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2000, 93, 135-140.	0.5	94
11	Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation. Journal of Bone and Mineral Metabolism, 2010, 28, 276-288.	1.3	94
12	Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. Clinical Cancer Research, 2014, 20, 6398-6405.	3.2	94
13	FcÂRIIIA and FcÂRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica, 2007, 92, 1127-1130.	1.7	89
14	Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab. Bone Marrow Transplantation, 2003, 32, 57-63.	1.3	88
15	Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia, 2001, 15, 976-980.	3.3	80
16	Nuclear Translocation of Heme Oxygenase-1 Confers Resistance to Imatinib in Chronic Myeloid Leukemia Cells. Current Pharmaceutical Design, 2013, 19, 2765-2770.	0.9	80
17	Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). Oncotarget, 2016, 7, 85764-85775.	0.8	80
18	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. Lancet Oncology, The, 2015, 16, 1506-1514.	5.1	76

#	Article	IF	Citations
19	Circulating myeloidâ€derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated upâ€front with a riskâ€adapted strategy. British Journal of Haematology, 2015, 168, 689-700.	1.2	76
20	Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients. PLoS ONE, 2014, 9, e101848.	1.1	71
21	Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study. Leukemia Research, 2014, 38, 57-64.	0.4	68
22	13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2011, 50, 633-643.	1.5	67
23	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget, 2017, 8, 79073-79086.	0.8	63
24	PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy. Expert Review of Molecular Diagnostics, 2018, 18, 675-683.	1.5	61
25	Primary analysis of JUMP, a phase 3b, expandedâ€access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. British Journal of Haematology, 2020, 189, 888-903.	1.2	61
26	Angiogenesis in Chronic Myeloproliferative Diseases. Acta Haematologica, 2001, 106, 177-183.	0.7	59
27	Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. British Journal of Haematology, 2015, 168, 361-370.	1.2	59
28	Flow cytometric detection of aneuploid CD38++ plasmacells and CD19+ B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leukemia Research, 2004, 28, 469-477.	0.4	57
29	Endoscopic features of gastro-intestinal lymphomas: From diagnosis to follow-up. World Journal of Gastroenterology, 2014, 20, 12993.	1.4	49
30	Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. Leukemia Research, 2004, 28, 367-372.	0.4	46
31	Iron toxicity â€“ Its effect on the bone marrow. Blood Reviews, 2018, 32, 473-479.	2.8	46
32	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. Hematological Oncology, 2018, 36, 561-569.	0.8	46
33	Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2. International Journal of Molecular Sciences, 2020, 21, 3622.	1.8	45
34	Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. Annals of Hematology, 2018, 97, 1009-1018.	0.8	44
35	Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives. Frontiers in Oncology, 2019, 9, 699.	1.3	43
36	Effects of imatinib mesylate in osteoblastogenesis. Experimental Hematology, 2009, 37, 461-468.	0.2	41

#	Article	IF	Citations
37	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer Journal, 2021, 11, 4.	2.8	41
38	The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis. Cells, 2019, 8, 1114.	1.8	40
39	Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma?. Annals of Oncology, 2007, 18, 351-356.	0.6	39
40	Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells. Biomolecules, 2020, 10, 696.	1.8	39
41	The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents. Blood Cancer Journal, 2017, 7, 649.	2.8	37
42	Î±-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload. International Journal of Molecular Sciences, 2019, 20, 609.	1.8	37
43	The Role of New Technologies in Myeloproliferative Neoplasms. Frontiers in Oncology, 2019, 9, 321.	1.3	37
44	Molecular Follow-Up of Disease Progression and Interferon Therapy in Chronic Myelocytic Leukemia. Blood, 1997, 90, 4918-4923.	0.6	36
45	Monocytic myeloidâ€derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib. Journal of Cellular and Molecular Medicine, 2018, 22, 1070-1080.	1.6	36
46	TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma. Cell Death and Disease, 2019, 10, 704.	2.7	36
47	Multidrug resistance mechanisms in chronic lymphocytic leukaemia. British Journal of Haematology, 2002, 116, 774-780.	1.2	35
48	BRIT1/MCPH1 Expression in Chronic Myeloid Leukemia and Its Regulation of the G2/M Checkpoint. Acta Haematologica, 2011, 126, 205-210.	0.7	34
49	Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview. Frontiers in Oncology, 2020, 10, 604143.	1.3	32
50	Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to AML. Leukemia Research, 2010, 34, 1539-1542.	0.4	31
51	Patientâ€reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. Cancer, 2018, 124, 1251-1259.	2.0	31
52	Nasal neutrophilia and eosinophilia induced by challenge with platelet activating factor. Journal of Allergy and Clinical Immunology, 1994, 93, 526-533.	1.5	30
53	A cytoprotective role for the heme oxygenaseâ€1/CO pathway during neural differentiation of human mesenchymal stem cells. Journal of Neuroscience Research, 2008, 86, 1927-1935.	1.3	30
54	Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients. PLoS ONE, 2016, 11, e0158392.	1.1	30

#	Article	IF	Citations
55	Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib. Redox Biology, 2020, 36, 101611.	3.9	30
56	Relationship between tumour necrosis factor Â and sex steroid concentrations in the follicular fluid of women with immunological infertility. Human Reproduction, 1996, 11, 265-268.	0.4	29
57	Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. Leukemia and Lymphoma, 2013, 54, 2458-2465.	0.6	29
58	Efficacy and safety of ruxolitinib in intermediateâ€1 IPSS risk myelofibrosis patients: Results from an independent study. Hematological Oncology, 2018, 36, 285-290.	0.8	29
59	Antitumor Activity of Bortezomib Alone and in Combination with Trail in Human Acute Myeloid Leukemia. Acta Haematologica, 2008, 120, 19-30.	0.7	28
60	Broad copy neutralâ€loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotypeâ€acute myeloid leukemia genomes. Genes Chromosomes and Cancer, 2010, 49, 1014-1023.	1.5	28
61	Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. British Journal of Haematology, 2003, 120, 405-412.	1.2	27
62	Effects of secondâ€generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors. Hematological Oncology, 2012, 30, 27-33.	0.8	26
63	Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma Cells. Cancers, 2020, 12, 1999.	1.7	25
64	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 3613-3622.	0.8	25
65	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter studyâŽ. Seminars in Hematology, 2018, 55, 248-255.	1.8	24
66	Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. Annals of Hematology, 2013, 92, 25-32.	0.8	23
67	Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. Experimental Hematology, 2014, 42, 126-136.e1.	0.2	23
68	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. Leukemia Research, 2018, 74, 86-88.	0.4	23
69	The use of erythropoiesisâ€stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. British Journal of Haematology, 2018, 182, 701-704.	1.2	22
70	Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53. Frontiers in Oncology, 2019, 9, 57.	1.3	22
71	The Role of Inflammation and Inflammasome in Myeloproliferative Disease. Journal of Clinical Medicine, 2020, 9, 2334.	1.0	22
72	Ixazomib Improves Bone Remodeling and Counteracts Sonic Hedgehog Signaling Inhibition Mediated by Myeloma Cells. Cancers, 2020, 12, 323.	1.7	22

#	Article	IF	Citations
73	Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genetics and Cytogenetics, 2010, 199, 110-120.	1.0	21
74	Deficiency and haploinsufficiency of histone macroH2A1.1 in mice recapitulate hematopoietic defects of human myelodysplastic syndrome. Clinical Epigenetics, 2019, 11, 121.	1.8	21
75	IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis. Aging, 2021, 13, 25055-25071.	1.4	21
76	The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma. BMC Medical Genomics, 2009, 2, 20.	0.7	20
77	Neutrophils Of Multiple Myeloma Are Dysfunctional and Immunosuppressive. Blood, 2013, 122, 3138-3138.	0.6	20
78	Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia. Frontiers in Pharmacology, 2017, 8, 204.	1.6	19
79	Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3. International Journal of Molecular Sciences, 2019, 20, 3548.	1.8	19
80	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. British Journal of Haematology, 2021, 193, 356-368.	1.2	19
81	CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment. Oncogenesis, 2022, 11, 6.	2.1	19
82	Early lenalidomide treatment for low and intermediateâ€1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusionÂdependence. Cancer Medicine, 2015, 4, 1789-1797.	1.3	18
83	The Efficacy of Rituximab plus Hyper-CVAD Regimen in Mantle Cell Lymphoma Is Independent of FCÎ³RIIIa and FCÎ³RIIa Polymorphisms. Journal of Chemotherapy, 2007, 19, 315-321.	0.7	17
84	Vascular Endothelial Growth Factor Polymorphisms in Mantle Cell Lymphoma. Acta Haematologica, 2010, 123, 91-95.	0.7	17
85	Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. Leukemia Research, 2015, 39, 859-865.	0.4	17
86	Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies. International Journal of Molecular Sciences, 2019, 20, 5459.	1.8	17
87	Immune offâ€target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma. British Journal of Haematology, 2019, 185, 468-479.	1.2	17
88	Angiogenesis in acute myeloid leukemia. Blood, 2000, 96, 3656-3659.	0.6	16
89	Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. Blood, 2020, 136, 37-38.	0.6	16
90	Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis. European Journal of Haematology, 2004, 72, 45-51.	1.1	15

#	Article	IF	Citations
91	SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation. BMC Cancer, 2013, 13, 60.	1.1	15
92	Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. Blood Reviews, 2019, 34, 16-25.	2.8	15
93	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Realâ€world data. Hematological Oncology, 2020, 38, 372-380.	0.8	15
94	A Physiological Role for the Neuropeptide Luteinizing Hormone-Releasing Hormone (LHRH) During the Maturation of Thymus Gland Function. International Journal of Neuroscience, 1990, 51, 287-289.	0.8	14
95	The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. Leukemia, 2020, 34, 2451-2459.	3.3	14
96	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. Cancer, 2021, 127, 2657-2665.	2.0	14
97	Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice. Annals of Hematology, 2020, 99, 65-72.	0.8	13
98	IGFBP-6: At the Crossroads of Immunity, Tissue Repair and Fibrosis. International Journal of Molecular Sciences, 2022, 23, 4358.	1.8	13
99	Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients. European Journal of Haematology, 2014, 93, 207-213.	1.1	12
100	Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review. International Journal of Molecular Sciences, 2020, 21, 3900.	1.8	12
101	Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens. Frontiers in Oncology, 2021, 11, 643490.	1.3	12
102	Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in longâ€term followâ€up. Hematological Oncology, 2012, 30, 180-185.	0.8	11
103	Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment. Annals of Hematology, 2018, 97, 745-754.	0.8	11
104	Comparison of JAK2^{V617F}â€positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology. Hematological Oncology, 2018, 36, 269-275.	0.8	11
105	The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. Journal of Clinical Epidemiology, 2021, 137, 31-44.	2.4	11
106	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. Blood, 2018, 132, 4277-4277.	0.6	11
107	Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma. Annals of Oncology, 2013, 24, 1038-1044.	0.6	10
108	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. Annals of Hematology, 2019, 98, 889-896.	0.8	10

#	Article	IF	Citations
109	Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes. International Journal of Molecular Sciences, 2021, 22, 486.	1.8	10
110	Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS). Blood, 2012, 120, 923-923.	0.6	10
111	Evaluation of taxol cytotoxicity on B-CLL cells in vitro. Leukemia and Lymphoma, 1997, 26, 115-119.	0.6	9
112	Pyrrolidinedithiocarbamate Induces Apoptosis in Human Acute Myelogenous Leukemic Cells Affecting NF-ÎºB Activity. Cancer Investigation, 2005, 23, 404-412.	0.6	9
113	Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. Journal of Hematology and Oncology, 2012, 5, 53.	6.9	9
114	Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicineâ€"Results from the Italian â€˜Back to Lifeâ€™ project. Quality of Life Research, 2018, 27, 1545-1554.	1.5	9
115	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. Hematological Oncology, 2021, 39, 409-418.	0.8	9
116	TLR4 Signaling and Heme Oxygenase-1/Carbon Monoxide Pathway Crosstalk Induces Resiliency of Myeloma Plasma Cells to Bortezomib Treatment. Antioxidants, 2022, 11, 767.	2.2	9
117	Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation. Bone Marrow Transplantation, 2012, 47, 24-32.	1.3	8
118	Immunoproteasome Genes Are Modulated in CD34+ JAK2V617F Mutated Cells from Primary Myelofibrosis Patients. International Journal of Molecular Sciences, 2020, 21, 2926.	1.8	8
119	Focus on Osteosclerotic Progression in Primary Myelofibrosis. Biomolecules, 2021, 11, 122.	1.8	8
120	Tryptophan Deprivation Promotes an Adaptive Response and Contributes to Bioenergetics in Multiple Myeloma. Blood, 2018, 132, 4511-4511.	0.6	8
121	In Vitro Sensitivity of B-CLL Cells to Fludarabine and Interferons. Leukemia and Lymphoma, 1995, 17, 449-453.	0.6	7
122	Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. Leukemia and Lymphoma, 2018, 59, 423-433.	0.6	7
123	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. British Journal of Haematology, 2018, 183, 35-46.	1.2	7
124	SARSâ€€CoVâ€2Âin Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. HemaSphere, 2020, 4, e483.	1.2	7
125	Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial. Blood, 2019, 134, 3000-3000.	0.6	7
126	Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial. Blood, 2015, 126, 91-91.	0.6	7

#	Article	IF	Citations
127	From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox. Frontiers in Oncology, 2021, 11, 752192.	1.3	7
128	Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUXâ€ΙOL study. British Journal of Haematology, 2022, 197, 190-200.	1.2	7
129	Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronicâ€phase myelofibrosis. Cancer, 2022, 128, 2449-2454.	2.0	7
130	Alternation of Epirubicin and Mitoxantrone in CHOP-like Regimens Retains Efficacy and Reduces Overall Toxicity in Elderly Patients with High and Intermediate Grade Non-Hodgkin Lymphomas. Leukemia and Lymphoma, 2002, 43, 2319-2324.	0.6	6
131	Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells. European Journal of Haematology, 2011, 86, 216-225.	1.1	6
132	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. Haematologica, 2015, 100, 517-524.	1.7	6
133	Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis. Blood, 2015, 126, 2799-2799.	0.6	6
134	ITF2357 interferes with apoptosis and inflammatory pathways in the HL-60 model: a gene expression study. Anticancer Research, 2010, 30, 4525-35.	0.5	6
135	Peptidergic modulation of immune system development: Role of luteinizing hormone-releasing hormone. Pharmacological Research, 1990, 22, 97-98.	3.1	5
136	Myeloid Impairment Contributes to Immunoparesis in Multiple Myeloma but Not MGUS. Blood, 2012, 120, 1831-1831.	0.6	5
137	Immunological Subsets Characterization in Newly Diagnosed Relapsingâ€“Remitting Multiple Sclerosis. Frontiers in Immunology, 2022, 13, 819136.	2.2	5
138	Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field. Cancers, 2022, 14, 2186.	1.7	5
139	Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis. Blood, 2016, 128, 1128-1128.	0.6	4
140	Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study. Turkish Journal of Haematology, 2015, 32, 206-212.	0.2	4
141	Proteomic and Genomic Profile of High-Risk MDS After Treatment with 5-Azacytidine,. Blood, 2011, 118, 3818-3818.	0.6	4
142	Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection. Cancers, 2022, 14, 1173.	1.7	4
143	Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases. Hematology Reports, 2022, 14, 67-72.	0.3	4
144	In vitro Apoptotic Response of Freshly Isolated Chronic Myeloid Leukemia Cells to all-trans Retinoic Acid and Cytosine Arabinoside. Acta Haematologica, 2000, 104, 57-64.	0.7	3

#	Article	IF	Citations
145	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. Hematological Oncology, 2019, 37, 418-423.	0.8	3
146	Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI). Leukemia and Lymphoma, 2022, 63, 189-198.	0.6	3
147	Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib. Blood, 2015, 126, 2767-2767.	0.6	3
148	Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233). Blood, 2016, 128, 3107-3107.	0.6	3
149	Angiogenesis in acute myeloid leukemia. Blood, 2000, 96, 3656-3659.	0.6	3
150	Myeloid-Derived Suppressor Cells in Patients with Hodgkin Lymphoma.. Blood, 2009, 114, 3662-3662.	0.6	3
151	Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience. Blood, 2018, 132, 4303-4303.	0.6	3
152	Neuroendocrine modulation of lymphocyte's activity during the physiological menstrual cycle. Pharmacological Research, 1990, 22, 101-102.	3.1	2
153	High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. International Journal of Hematology, 2020, 112, 141-146.	0.7	2
154	The first description of a singular case of synchronous chronic myelomonocytic leukemia and diffuse large bâ€cell lymphoma. Clinical Case Reports (discontinued), 2021, 9, e03817.	0.2	2
155	Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience. Blood, 2019, 134, 839-839.	0.6	2
156	Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis. Blood, 2016, 128, 4251-4251.	0.6	2
157	In Vitro and in Vivo Evidence of an Anti-Angiogenic Effect of Lenalidomide in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 1782-1782.	0.6	2
158	Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. Blood, 2019, 134, 4174-4174.	0.6	2
159	Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL). Blood, 2020, 136, 16-17.	0.6	2
160	Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes. Journal of Clinical Medicine, 2022, 11, 1665.	1.0	2
161	In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection. Scientific Reports, 2022, 12, 7237.	1.6	2
162	Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance. Current Oncology, 2022, 29, 4970-4980.	0.9	2

#	Article	IF	Citations
163	Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients. Blood, 2018, 132, 2293-2293.	0.6	1
164	CD200 Expression May Help in Differential Diagnosis between Mantle Cell Lymphoma (MCL) and B-Cell Chronic Lymphocytic Leukemia (B-CLL).. Blood, 2007, 110, 4672-4672.	0.6	1
165	Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells. Blood, 2012, 120, 5005-5005.	0.6	1
166	Human Macrophages Phagocytose Rituximab Opsonised Leukemic Cells Via CD16, CD32 and CD64 but Do Not Mediate ADCC.. Blood, 2006, 108, 2507-2507.	0.6	1
167	Role of Imatinib Mesylate in Osteoblastogenesis.. Blood, 2007, 110, 1928-1928.	0.6	1
168	Myeloid Cells Exert Immunosuppressive Activity and Have Prognostic Value In Hodgkin Lymphoma. Blood, 2013, 122, 4238-4238.	0.6	1
169	Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. Blood, 2019, 134, 4184-4184.	0.6	1
170	Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study. Blood, 2019, 134, 4179-4179.	0.6	1
171	Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Policythemia Vera Resistant/Intolerant to Hydroxyurea. Blood, 2021, 138, 2581-2581.	0.6	1
172	Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival. Blood, 2020, 136, 17-18.	0.6	1
173	Emangioma, plasmocitoma e mieloma multiplo del rachide. The Neuroradiology Journal, 2002, 15, 445-450.	0.1	0
174	Erythrocytapheresis is a valid and safe therapeutic option in dysmetabolic iron overload syndrome. Journal of Clinical Apheresis, 2016, 31, 443-447.	0.7	0
175	Tryptophan Shortage Due to IDO-1 Expressed by High-Density Neutrophils Induce Immune-Suppression and Plasma Cell Fitness in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S246.	0.2	0
176	TLR4 signaling drives mesenchymal stromal cells (MSC) commitment to promote tumor microenvironment transformation in multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e90-e91.	0.2	0
177	Ixazomib inhibits osteoclastogenesis and promotes osteogenic differentiation in vitro. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e195.	0.2	0
178	Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters. Hemato, 2021, 2, 347-352.	0.2	0
179	In Vitro Cytotoxicity of Alemtuzumab on B-CLL Cells: Differential Effect on B and T Lymphocytes.. Blood, 2006, 108, 4981-4981.	0.6	0
180	Hypoxia Induces Imatinib Resistance in CML Cell Lines.. Blood, 2006, 108, 4387-4387.	0.6	0

#	Article	IF	Citations
181	Effect of Hypoxia on the Expression of BRIT1 in K562 Cell Line: Implication for Resistance to Imatinib.. Blood, 2007, 110, 4530-4530.	0.6	0
182	Salvage Therapy with Intravenous Bortezomib, Melphalan and Dexamathasone in Previously Treated Myeloma Patients.. Blood, 2007, 110, 2728-2728.	0.6	0
183	Antitumor Activity of Bortezomib Alone and in Combination with TRAIL in Human Acute Myeloid Leukemia.. Blood, 2007, 110, 4307-4307.	0.6	0
184	Role of New Tyrosine Kinase Inhibitors in Osteoblastogenesis. Blood, 2008, 112, 4751-4751.	0.6	0
185	Variation of T-Reg and CD 200+ T- Lymphocytes After in Vitro Treatment with Active Drugs against CLL.. Blood, 2009, 114, 1239-1239.	0.6	0
186	Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma. Blood, 2010, 116, 3882-3882.	0.6	0
187	A Prospective, Multi Center Phase II Study Evaluating Predictive Factors for Lenalidomide Treatment in Relapse or Refractory Chronic Lymphocytic Leukemia Patients (LE.P.RE.): Preliminary Results about the First 20 Enrolled Patients. Blood, 2011, 118, 1782-1782.	0.6	0
188	Heme Oxygenase 1-Induced Resistance to Imatinib In Chronic Myelogenous Leukemia Cells. Blood, 2011, 118, 4410-4410.	0.6	0
189	Myeloid-Derived Suppressor Cells Increase in Chronic Myeloid Leukemia and Exert Immune Suppressive Activity.. Blood, 2012, 120, 2779-2779.	0.6	0
190	Patient-Reported Fatigue, Functional Aspects and Quality of Life in Elderly Patients with High-Risk Myelodysplastic Syndromes. Evidence From a Large Prospective International Study.. Blood, 2012, 120, 3163-3163.	0.6	0
191	Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity In CML Patients At Diagnosis. Blood, 2013, 122, 2711-2711.	0.6	0
192	JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome. Blood, 2015, 126, 1614-1614.	0.6	0
193	Mesenchymal STEM CELLS Favor Tumor Growth By Generating Granulocyte-like Myeloid Derived Suppressor CELLS in CML Patients. Blood, 2015, 126, 4018-4018.	0.6	0
194	Inclusion of Patient's Self-Reported Fatigue into a Standard Laboratory Risk Classification Enhances Survival Prediction in Patients with Advanced Myelodysplastic Syndromes. Blood, 2016, 128, 1242-1242.	0.6	0
195	Presentation and Outcome of 199 Patients with 2016 Who Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. Blood, 2018, 132, 3052-3052.	0.6	0
196	Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI). Blood, 2018, 132, 4312-4312.	0.6	0
197	Role of TLR4 in the Activation of a Pro-Tumor Phenotype of Mesenchymal Stromal Cells in Mutiple Myeloma. Blood, 2018, 132, 1892-1892.	0.6	0
198	Pretreatment symptom prevalence in patients with myelodysplastic syndromes (MDS) across all disease risk categories: Analysis of 914 patients.. Journal of Clinical Oncology, 2019, 37, e18220-e18220.	0.8	0

#	Article	IF	Citations
199	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. Blood, 2019, 134, 4166-4166.	0.6	0
200	Inhibition of TLR4 Signaling Affects Mitochondrial Fitness Overcoming Bortezomib Resistance in Myeloma Plasma Cells. Blood, 2019, 134, 3073-3073.	0.6	0
201	Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study. Blood, 2019, 134, 4188-4188.	0.6	0
202	Ixazomib Modulates Bone Remodeling and Actives Sonic Hedgehog Pathways. Blood, 2019, 134, 4345-4345.	0.6	0
203	Bortezomib-Based Transplantation and Consolidation Therapy Followed by Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma. SSRN Electronic Journal, 0, , .	0.4	0
204	Effects of micronised microencapsulated ferric pyrophosphate supplementation in patients with advanced cancer and iron deficiency: a single-centre cohort pilot study. Blood Transfusion, 2019, 17, 196-199.	0.3	0
205	Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality. American Journal of Blood Research, 2021, 11, 417-426.	0.6	0
206	CXCL12/CXCR4 Axis Drives Mitochondrial Trafficking in Tumor Myeloma Microenvironment. Blood, 2021, 138, 2663-2663.	0.6	0
207	Lactate As Metabolic Link between Cancer Cells and Tumor Microenvironment in Myelofibrosis Patients. Blood, 2020, 136, 26-26.	0.6	0
208	The Heme Oxygenase-1/Carbon Monoxide Pathway Activates TLR4 Signaling Promoting Bortezomib Resistance in Multiple Myeloma Cells. Blood, 2020, 136, 13-14.	0.6	0
209	Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. Blood, 2020, 136, 49-50.	0.6	0
210	First Line Treatment with Hydroxyurea in Patients with Policitemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria. Blood, 2020, 136, 43-44.	0.6	0